Filtricine, Inc., is a pre-clinical biotechnology company working toward FDA approval of therapeutic products for a novel type of cancer treatment. Backed by venture capital, and located in the San Francisco Bay Area of California.

We are developing an innovative cancer therapy through targeted deprivation of the nutrients that are critical to the growth of cancer cells only. This breakthrough technology emerged from research performed at Stanford University.

 

A Novel Approach to Cancer Treatment.gif

A Novel Approach to Cancer Treatment

Engineering the Death of Cancer Cells

The hyperactive metabolism of cancer cells is extensively modified to support their unsustainable consumption of nutrients, which is what allows cancer cells to reproduce rapidly. Yet cancer cells lose their ability to make certain nutrients on their own like healthy cells do. Instead, cancer cells must obtain these nutrients from the bloodstream and from body fluid. Our proprietary therapy demonstrates that when supply of these nutrients is cut off, cancer cells die—whereas healthy cells continue to grow as they normally would.

filtricine with without.jpg

Our Innovative Technologies Attack Cancer Cells

Our strategy is to eliminate target nutrients—some non-essential amino acids—in the patient’s bloodstream.

The first technology is a nutrient deprivation therapy that, when used exclusively by patients during the treatment protocol, can cut off the supply of target nutrients, thereby causing cancer cell death. Non-cancerous cells continue to receive all necessary nutrients needed to remain healthy.

When treated by our products, the cancer cells exhaust their internal supply of these specific amino acids, and soon the cells are starved of their nutritional needs. As a result, tumor growth slows or even stops, and the patient’s medical condition improves.

To further enhance the efficacy of our novel cancer treatment, Filtricine is also developing a powerful add-on technology: modified dialysis. Modified dialysis could help achieve faster and more efficient targeted nutrient deprivation, with the goal of ultimately clearing cancer cells from the body.

 
hands holding.jpg

Filtricine vs Other Cancer Treatments

Our therapy removes specific amino acids that cancer cells need to survive; it does not deliver toxic compounds to cancer cells. This may confer unique advantages to our therapy such as reduced toxicity and broad applicability, even for solid tumors that are challenging for other therapies to penetrate and target effectively, such as brain and pancreatic cancers.

Therefore, a key potential benefit of our therapy is its ability to target cancer cells originating from nearly all types of cancer.

Moreover, our pre-clinical research indicates that, over six months, there was no resistance to our nutrient deprivation therapy. This stands in contrast to certain cancer treatments that, when used over time, can result in the development of therapy resistance.


We would like to hear from you.

Name *
Name